|Systematic (IUPAC) name|
|Biological half-life||3 to 9 hours|
|CAS Registry Number|
Ethotoin (marketed as Peganone by Ovation) is an anticonvulsant drug used in the treatment of epilepsy. It is a hydantoin, similar to phenytoin. Ethotoin lacks phenytoin's side effects of gingival hyperplasia and hirsutism; however, it is less effective. This, combined with the need for frequent dosing has limited its usefulness. Ethotoin is no longer widely used.
- Mechanism of action 1
- Approval history 2
- Indications and usage 3
- Dosing 4
- Side effects 5
- Chemistry 6
- References 7
- External links 8
Mechanism of action
Similar to phenytoin.
- 1957 Peganone was granted Food and Drug Administration (FDA) approval to Abbott Laboratories for treatment of grand mal (tonic clonic) and partial complex (psychomotor) seizures.
- 2003 Peganone was acquired from Abbott Laboratories by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
Indications and usage
Ethotoin is indicated for tonic-clonic and partial complex seizures.
Ethotoin is available in 250mg tablets. It is taken orally in 4 to 6 divided doses per day, preferably after food.
Ethotoin, 3-ethyl-5-phenylimidazolidine-2,4-dione, is synthesized by the reaction of benzaldehyde oxynitrile, with urea or ammonium hydrocarbonate, which forms an intermediate urea derivative which on acidic conditions cyclizes to 5-phenylhydantoin. Alkylation of this product using ethyliodide leads to the formation of ethotoin.
- A. Pinner, Chem. Ber., 21, 2324 (1888).
- W.J. Close, U.S. Patent 2,793,157 (1946).
- Drugs.com: Ethotoin
- PEGANONE 250 mg Ethotoin Tablets, USP (PDF)
- Ovation Pharmaceuticals